

## Article

# T cell repertoire dynamics during pregnancy in multiple sclerosis

Ramien, Caren, Engler, Jan B, Gamradt, Stefanie, Patas, Kostas, Schweingruber, Nils, Willing, Anne, Rosenkranz, Sina, Diemert, Anke, Fischer, Anja, Vignali, Marissa, Sanders, Catherine, Robins, Harlan S, Tolosa, Eva, Heesen, Christoph, Arck, Petra C, Scheffold, Alexander, Chan, Kenneth, Emerson, Ryan O, Friese, Manuel A and Gold, Stefan M

Available at <http://clock.uclan.ac.uk/29509/>

*Ramien, Caren, Engler, Jan B, Gamradt, Stefanie, Patas, Kostas, Schweingruber, Nils, Willing, Anne, Rosenkranz, Sina, Diemert, Anke, Fischer, Anja ORCID: 0000-0002-7872-1292 et al (2019) T cell repertoire dynamics during pregnancy in multiple sclerosis. Cell reports, 29 (4). pp. 810-815. ISSN 2211-1247*

It is advisable to refer to the publisher's version if you intend to cite from the work.

<http://dx.doi.org/10.1016/j.celrep.2019.09.025>


For more information about UCLan's research in this area go to <http://www.uclan.ac.uk/researchgroups/> and search for <name of research Group>.

For information about Research generally at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

## T Cell Repertoire Dynamics during Pregnancy in Multiple Sclerosis

### Graphical Abstract



### Authors

Caren Ramien, Erik C. Yusko, Jan Broder Engler, ..., Ryan O. Emerson, Manuel A. Friese, Stefan M. Gold

### Correspondence

stefan.gold@charite.de

### In Brief

Ramien et al. interrogate the immune repertoire in multiple sclerosis (MS) during pregnancy. They report a shift in T cell repertoire composition driven by a small number of “private” clones. This specific rather than global immunomodulation may help to explain the protective effect of pregnancy in human autoimmunity.

### Highlights

- Pregnancy modulates the T cell repertoire in MS in a clonally specific fashion
- “Private” candidate clones associated with disease activity can be identified
- Barcoding enables  $\alpha$ - $\beta$  TCR pairing of these clones for further characterization
- Most candidate clones do not respond to putative MS autoantigens (e.g., myelin)



# T Cell Repertoire Dynamics during Pregnancy in Multiple Sclerosis

Caren Ramien,<sup>1,12</sup> Erik C. Yusko,<sup>7,12</sup> Jan Broder Engler,<sup>1</sup> Stefanie Gamradt,<sup>8</sup> Kostas Patas,<sup>1,11</sup> Nils Schweingruber,<sup>1,5</sup> Anne Willing,<sup>1</sup> Sina Cathérine Rosenkranz,<sup>1,5</sup> Anke Diemert,<sup>2</sup> Anja Harrison,<sup>1,6</sup> Marissa Vignali,<sup>7</sup> Catherine Sanders,<sup>7</sup> Harlan S. Robins,<sup>7,10</sup> Eva Tolosa,<sup>4</sup> Christoph Heesen,<sup>1,5</sup> Petra C. Arck,<sup>3</sup> Alexander Scheffold,<sup>9</sup> Kenneth Chan,<sup>7</sup> Ryan O. Emerson,<sup>7,13</sup> Manuel A. Friese,<sup>1,13</sup> and Stefan M. Gold<sup>1,8,13,14,\*</sup>

<sup>1</sup>Institut für Neuroimmunologie und Multiple Sklerose (INIMS), Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany

<sup>2</sup>Klinik für Geburtshilfe und Pränatalmedizin, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany

<sup>3</sup>Labor für Experimentelle Feto-Maternale Medizin, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany

<sup>4</sup>Institut für Immunologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany

<sup>5</sup>Klinik für Neurologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany

<sup>6</sup>Department of Psychology, University of Central Lancashire, Preston, PR1 2HE Lancashire, UK

<sup>7</sup>Adaptive Biotechnologies Corp., 1551 Eastlake Ave. E., Seattle, WA 98102, USA

<sup>8</sup>Charité - Universitätsmedizin Berlin, Klinik für Psychiatrie und Medizinische Klinik m.S. Psychosomatik, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany

<sup>9</sup>Institut für Immunologie, Universitätsklinikum Schleswig-Holstein, Arnold Heller Str. 3, 24105 Kiel, Germany

<sup>10</sup>Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109-1024, USA

<sup>11</sup>Laboratory for Biopathology and Immunology, Eginition University Hospital, 72-74 Vasilissis Sophias Ave., 11528 Athens, Greece

<sup>12</sup>These authors contributed equally

<sup>13</sup>Senior author

<sup>14</sup>Lead Contact

\*Correspondence: [stefan.gold@charite.de](mailto:stefan.gold@charite.de)  
<https://doi.org/10.1016/j.celrep.2019.09.025>

## SUMMARY

Identifying T cell clones associated with human autoimmunity has remained challenging. Intriguingly, many autoimmune diseases, including multiple sclerosis (MS), show strongly diminished activity during pregnancy, providing a unique research paradigm to explore dynamics of immune repertoire changes during active and inactive disease. Here, we characterize immunomodulation at the single-clone level by sequencing the T cell repertoire in healthy women and female MS patients over the course of pregnancy. Clonality is significantly reduced from the first to third trimester in MS patients, indicating that the T cell repertoire becomes less dominated by expanded clones. However, only a few T cell clones are substantially modulated during pregnancy in each patient. Moreover, relapse-associated T cell clones identified in an individual patient contract during pregnancy and expand during a postpartum relapse. Our data provide evidence that profiling the T cell repertoire during pregnancy could serve as a tool to discover and track “private” T cell clones associated with disease activity in autoimmunity.

## INTRODUCTION


Identification of relevant T cell clones in complex human autoimmune disorders has remained challenging due to the enormous

interindividual variability in repertoire composition and diversity (Hohlfeld et al., 2016a, 2016b). Therefore, cross-sectional case-control studies have limited power and are unlikely to yield informative differences at the group level. Rather, identifying such clones, which are likely “private” (i.e., specific to individual patients), will require longitudinal assessments over periods with rapid changes of disease activity and remission. Pregnancy has a pronounced and clinically relevant impact on maternal autoimmunity, as reflected by a protective effect of pregnancy on disease activity of many autoimmune disorders (Barrett et al., 1999; Confavreux et al., 1998; de Man et al., 2008; Finkelsztejn et al., 2011). In multiple sclerosis (MS), the relapse rate is reduced by 70%–80% in the third trimester (Confavreux et al., 1998; Finkelsztejn et al., 2011), which exceeds the effectiveness of many of the currently available therapies for this disease. Thus, pregnancy could serve as a highly informative research paradigm to uncover relevant T cell clones in individual patients with autoimmune disorders.

Pregnancy is also interesting from an evolutionary perspective, as it poses a challenge to the maternal immune system in placental mammals to balance prevention of immune attacks against the fetus while maintaining immunocompetence of the mother against infections. Strong evolutionary pressure on reproduction has led to highly specific immune adaptation to mammalian pregnancy (Samstein et al., 2012) and can thus offer insights into mechanisms of endogenous immune tolerance.

Many pregnancy hormones have immunomodulatory properties that could exert nonspecific effects to mediate this phenomenon (Gold and Voskuhl, 2016), and pregnancy protection from autoimmunity in animal models depends on intact endocrine regulation of T cells (Engler et al., 2017). However, exogenous





**Figure 1. Pregnancy Shifts Clonal Composition of the T Cell Repertoire**

(A and B) T cell clonality tracked during pregnancy in PBMCs of female patients with MS (A) and healthy pregnant women (B). A decrease in clonality indicates that the T cell repertoire is less dominated by expanded clones and becomes more evenly distributed.

(C) Degree of absolute and relative change of T cell clonality in PBMCs from trimester 1 to trimester 3, contrasted between MS patients and healthy controls.

(D and E) T cell clonality of CD8<sup>+</sup> (D) and CD4<sup>+</sup> T cells (E) tracked during pregnancy in MS patients.

Data are shown as individual data points per subject ( $n = 11$ , MS;  $n = 12$ , HC), including median;  $p$  values are derived from a Wilcoxon matched-pairs signed rank test comparing trimester 1 to trimester 3 (A, B, D, and E) and a Mann-Whitney  $U$  test comparing groups (C). See also Figures S1 and S2.

application of these hormones does not fully replicate the protective effect of pregnancy on MS (Pozzilli et al., 2015; Voskuhl et al., 2016). Moreover, animal models have indicated that cell-mediated, antigen-specific mechanisms contribute substantially to the establishment of temporary immune tolerance during pregnancy (Engler et al., 2017; Kahn and Baltimore, 2010; Munoz-Suano et al., 2012; Rowe et al., 2012). If evidence were found that pregnancy modulates the human maternal immune system in a specific rather than a global fashion, then this could help to unravel antigen-specific tolerance mechanisms, with potential implications for autoimmune disease, transplantation, and reproductive health.

## RESULTS

### Pregnancy Alters T Cell Clonality in MS

To test this hypothesis, we employed high-throughput immunosequencing, which allows characterization of the T cell repertoire at the single-clone level, before pregnancy, at three different time points during pregnancy (first, second, and third trimester), and at 3 months postpartum in a cohort of healthy women ( $n = 12$ ) and a cohort of female MS patients ( $n = 11$ ). To control for potential confounders, cases and controls were matched for age of the mother, sex of the child, and parity (i.e., number of previous children), with most of the participating women delivering their first child in this study (see Table S1).


As a measure of T cell repertoire diversity, we first examined clonal composition in peripheral blood mononuclear cells (PBMCs) and detected a significant decrease in clonality during pregnancy in MS patients, but not in healthy controls (Figures 1A and 1B). MS patients showed significantly stronger downmodulation of T cell clonality from trimester 1 to trimester 3 compared to controls in terms of both absolute and relative change (Figure 1C), with large effect sizes ( $d = 1.03$  and  $d = 1.17$  for absolute and relative change, respectively). We further confirmed a differential effect of pregnancy on clonality using a general linear model as a sensitivity analysis (main effect for time  $F = 8.83$ ;

degrees of freedom [df] = 2; error df = 20;  $p = 0.002$ ; effect size partial  $\eta^2 = 0.469$  as well as a significant time\*group interaction  $F = 3.95$ ; df = 2; error df = 20;  $p = 0.036$ ; effect size partial  $\eta^2 = 0.283$ ). This indicates that during MS pregnancy, the T cell repertoire becomes more evenly distributed and less dominated by expanded clones. Repertoire analysis in CD4<sup>+</sup> and CD8<sup>+</sup> T cells confirmed decreasing clonality during pregnancy in MS patients in both subsets (Figures 1D and 1E).

Of note, no statistically significant differences in T cell clonality between MS patients and healthy controls (CD8  $p = 0.41$ ; CD4  $p = 0.08$ ; PBMCs  $p = 0.48$ ) were observed at the earliest time point (trimester 1), further underscoring the large interindividual variability and the importance of searching for clones in individuals over time rather than cross-sectionally between cases and controls. Moreover, tracking T cell repertoire clonality in  $n = 3$  healthy young non-pregnant women over the course of 13 months showed some fluctuations over time in each individual but no discernable pattern (see Figure S1), lending support to the notion that the pregnancy effect in MS patients is unlikely to be simply explained by random variability. The total number of circulating T cells was unaltered during pregnancy, and few significant changes were observed in relative CD4<sup>+</sup> and CD8<sup>+</sup> frequencies or their general phenotype (see Figure S2). For example, we observed significant reductions in CD45RO-expressing CD4<sup>+</sup> and CD8<sup>+</sup> cells of MS patients during pregnancy (but not healthy controls), indicating that predominantly antigen-experienced T cells were downmodulated by pregnancy (Figures S2E and S2F).

### Pregnancy Significantly Modulates a Small Number of Private T Cell Clones

Next, we sought to identify which clones were responsible for driving the observed changes in T cell repertoire clonality. Pronounced and statistically significant pregnancy effects were seen for the 25 most abundant clonotypes in each MS patient (Figures 2A and 2C), but not in healthy controls (Figures 2B and 2D). Again, absolute as well as relative downregulation in



**Figure 2. Dynamics of Most Frequent Clonotypes in Pregnancy**

(A and B) Heatmap plotting the frequency of the most abundant 25 T cell clonotypes in bulk PBMCs in each MS patient (A) and each healthy control (B) tracked over the course of pregnancy.

(C and D) Quantification of clonotypes shown in (A) and (B), respectively.

(E and F) Degree of absolute (E) and relative change (F) of cumulative frequency of top 25 clonotypes in PBMCs from trimester 1 to trimester 3, contrasted between MS patients and healthy controls.

(G) Number of unique clones identified in each MS patient that significantly contracted from trimester 1 to trimester 3 trimester and re-expanded from trimester 3 to the postpartum time point (adjusted for multiple comparisons).

Data are shown as individual data points per subject ( $n = 11$ , MS;  $n = 12$ , MS) and median;  $p$  values are derived from a Wilcoxon matched-pairs signed rank test comparing trimester 1 to trimester 3 (C and D) and a Mann-Whitney  $U$  test comparing groups (E and F).

See also [Figure S1](#).

cumulative frequency of the top 25 clonotypes from trimester 1 to trimester 3 was significantly larger in MS patients compared to controls ([Figures 2E and 2F](#)).


Then, we identified T cell clones that showed a frequency pattern mirroring the clinical effect of pregnancy in MS, i.e., (1) contracting from trimester 1 to trimester 3, and (2) re-expanding post partum, based on a statistical algorithm and adjusted for multiple comparisons (“candidate clones”; see [STAR Methods](#)). We were able to detect clones that followed this pattern in the majority of patients (9 out of 11; [Figure 2G](#)), with two notable exceptions: one patient who experienced a relapse during pregnancy (MS41) and another patient (MS23) treated with a disease-modifying therapy (DMT) (dimethyl fumarate) directly after delivery. All other patients had between 5 and 40 unique clones that met our statistical criteria. The vast majority of these clones were found only in a single patient, indicating that they largely represent private clones (see [Data S1](#)). By applying the pairSEQ approach ([Howie et al., 2015](#)), we were able to successfully identify the corresponding  $\alpha$  chain for 1,774 unique T cell clones including most of the candidate clones, thereby yielding the T cell receptor (TCR) sequence described by its V gene, CDR3, and J gene (see [Data S1](#) for

a complete list of candidate clones and their frequencies tracked longitudinally over the course of pregnancy and postpartum).

### T Cell Receptor Sequencing in an Individual Patient Identifies Relapse-Associated T Cell Clones

Next, we explored the ability of our approach to identify and track relapse-associated clones in an individual patient.

Patient MS15 showed the largest number of modulated clones during pregnancy and postpartum ([Figure 2G](#)) and also experienced a clinical relapse (optic neuritis) at the 3-month postpartum time point ([Figure 3A](#)). This case is particularly informative, as it mirrors the epidemiological pattern of MS disease activity during pregnancy. Therefore, we first identified the clonotypes with the highest frequencies during the postpartum relapse (i.e., top 100 clonotypes) and tracked them retrospectively over the course of pregnancy. These relapse-associated clones showed a statistically significant reduction over the course of pregnancy, with the lowest frequencies in the third trimester ([Figures 3B and 3C](#)), observable in both CD4<sup>+</sup> and CD8<sup>+</sup> cells. Of note, 23 of the 40 candidate clones identified for MS15 above (see [Figure 2G](#)) were among the top 100 CD8<sup>+</sup> relapse-associated clonotypes. In contrast, there was no significant pregnancy effect on frequencies of myelin- or EBNA-1-specific T cells ([Figure S4](#); [Data S2](#)). Moreover, only three EBNA-1-specific (but no myelin-specific) CD4<sup>+</sup> T cell clonotypes were detected in the top 100 relapse-associated CD4<sup>+</sup> T cell clonotypes (see [Figure 3](#)). Together, these data imply that sequencing the TCR during pregnancy in individual patients can yield a substantial number of



**Figure 3. Tracking of Postpartum-Relapse-Associated Clonotypes and Antigen-Specific Clonotypes in Patient MS15**

(A) Patient MS15 experienced a postpartum relapse at the time of assessment but had no MS symptoms at any of the time points during pregnancy, therefore providing an opportunity to track relapse-associated and antigen-specific clones during pregnancy.

(B and C) Heatmaps tracking the 100 most abundant T cell clonotypes present during the postpartum relapse over the course of pregnancy are shown for CD8<sup>+</sup> (B) and CD4<sup>+</sup> compartment (C) with the corresponding quantifications in the panels below. In (B) and (C), candidate clonotypes (see Figure 2G) and EBNA-1-specific clonotypes found among the relapse associated clonotypes are marked as a black circle or black diamond, respectively.

Data are shown as individual clonotypes (n = 100), including median; p values are derived from Wilcoxon matched-pairs signed rank test comparing trimester 1 to trimester 3. HLA genotype of MS15: A \*0101/1101; B \*0801/3503; DRB1 \*0408/1301; DQA1 \*0103/03XX; DQB1 \*0304/0603.

See also Figures S3 and S4.

potentially relevant clones beyond “classical” putative MS-related antigens such as myelin or EBV.

## DISCUSSION

Together, our data demonstrated that pregnancy in MS significantly alters clonal composition of T cells toward a more evenly distributed repertoire driven by selective downregulation of a few largely private T cell clones.

Despite evidence that both CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets play a prominent role in MS pathogenesis (Dendrou et al., 2015), identifying disease-relevant and autoantigen-specific T cells in MS has remained challenging for both subsets (Hohlfeld et al., 2016a, 2016b). TCR sequencing approaches have shed light onto the clonal composition of CNS-infiltrating T cells in MS (e.g., Jelcic et al., 2018; Planas et al., 2018), but little is known

about the T cell dynamics *in vivo* during times of disease activity and remission. In human subjects in general and pregnant women in particular, such research is obviously limited to correlational analyses, and we cannot infer causality from our data. However, our approach illustrates that pregnancy could be a “window” to the dysregulated immune system leading to the identification of private T cell clones *in vivo* that are associated with disease activity in individual patients. Importantly, our analysis indicates that clones that exhibit the biggest frequency shifts during times of clinical inactivity (e.g., during pregnancy) versus inflammatory exacerbation (e.g., postpartum relapse) are typically private (i.e., unique to individual patients). Moreover, CD4<sup>+</sup> T cells specific to putative disease-related antigens in MS such as myelin or Epstein-Barr virus (EBV) do not seem to contribute substantially to the most strongly modulated T cell clonotypes. This highlights the need for personalized approaches to identify and track these clones longitudinally in individual patients rather than cross-sectional case-control comparisons.

We acknowledge some limitations of our study. Patients and healthy controls were well characterized and closely matched on clinical characteristics (but not on human leukocyte antigen [HLA]). However, the sample was still comparatively small, and the study should thus be considered exploratory. Moreover, the functional characteristics and antigen specificity of identified clones are presently unknown. Recent studies have demonstrated pregnancy effects on intracellular signaling (Aghaeepour et al., 2017) and epigenetic signatures (Iannello et al., 2019) in the immune system, and such characterizations in unique T cell clones (Han et al., 2014) could help to better understand the molecular drivers of T cell repertoire changes. Given that the findings we describe herein allow the deciphering of the full receptor based on its V gene, J gene, and CDR3 sequence of the  $\alpha$  and  $\beta$  chains of the TCR, such studies are now within reach. As a result, immune profiling during pregnancy could open additional avenues for identifying private T cell clones associated with disease activity in individual patients that could eventually be specifically targeted.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Subjects and recruitment
- METHOD DETAILS
  - Blood sampling and processing
  - Flow cytometry
  - Identification of antigen-specific CD4<sup>+</sup> T cells
  - Cell purification and DNA extraction
  - Immunosequencing
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND CODE AVAILABILITY

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2019.09.025>.

**ACKNOWLEDGMENTS**

This work was supported by the Deutsche Forschungsgemeinschaft (grants GO1357/8-1, GO1357/8-2, FR1720/8-1, FR1720/8-2, KFO296 Feto-maternal Immune Cross-Talk to S.M.G. and M.A.F. and grant GO1357/5-2 to S.M.G.).

**AUTHOR CONTRIBUTIONS**

S.M.G. and M.A.F. conceived the study and acquired funding. C.R., K.P., A.W., S.C.R., A.D., A.H., C.H., P.C.A., M.A.F., and S.M.G. planned and conducted patient recruitment, follow-up, and sample collection. S.M.G., E.T., A.S., C.S., and M.V. designed the experiments. C.R., K.P., S.G., N.S., E.C.Y., M.V., K.C., C.S., R.O.E., and H.S.R. conducted experiments. C.R., E.C.Y., S.G., N.S., J.B.E., K.C., and S.M.G. analyzed the data. C.R., E.C.Y., K.P., S.G., J.B.E., N.S., A.W., M.V., C.S., H.S.R., A.S., K.C., R.O.E., M.A.F., and S.M.G. interpreted the data. C.R., S.G., J.B.E., and S.M.G. designed figures and tables. S.M.G. wrote the manuscript. All authors critically revised the manuscript for intellectual content.

**DECLARATION OF INTERESTS**

E.C.Y., C.S., H.S.R., K.C., M.V., and R.O.E. have or had employment and equity ownership with Adaptive Biotechnologies. H.S.R. and R.O.E. report patents related to this work. A.S. is a consultant of Miltenyi Biotec, which has patents related to this work. The remaining authors declare no competing interests.

Received: May 31, 2018

Revised: July 10, 2019

Accepted: September 6, 2019

Published: October 22, 2019

**REFERENCES**

- Aghaepour, N., Ganio, E.A., McIlwain, D., Tsai, A.S., Tingle, M., Van Gassen, S., Gaudilliere, D.K., Baca, Q., McNeil, L., Okada, R., et al. (2017). An immune clock of human pregnancy. *Sci. Immunol.* **2**, eaan2946.
- Bacher, P., Schink, C., Teutschbein, J., Kniemeyer, O., Assenmacher, M., Brakhage, A.A., and Scheffold, A. (2013). Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. *J. Immunol.* **190**, 3967–3976.
- Barrett, J.H., Brennan, P., Fidler, M., and Silman, A.J. (1999). Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. *Arthritis Rheum.* **42**, 1219–1227.
- Carlson, C.S., Emerson, R.O., Sherwood, A.M., Desmarais, C., Chung, M.-W., Parsons, J.M., Steen, M.S., LaMadrid-Herrmannsfeldt, M.A., Williamson, D.W., Livingston, R.J., et al. (2013). Using synthetic templates to design an unbiased multiplex PCR assay. *Nat. Commun.* **4**, 2680.
- Confavreux, C., Hutchinson, M., Hours, M.M., Cortinovis-Tourniaire, P., and Moreau, T.; Pregnancy in Multiple Sclerosis Group (1998). Rate of pregnancy-related relapse in multiple sclerosis. *N. Engl. J. Med.* **339**, 285–291.
- de Man, Y.A., Dolhain, R.J., van de Geijn, F.E., Willemsen, S.P., and Hazes, J.M. (2008). Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. *Arthritis Rheum.* **59**, 1241–1248.
- Dendrou, C.A., Fugger, L., and Friese, M.A. (2015). Immunopathology of multiple sclerosis. *Nat. Rev. Immunol.* **15**, 545–558.
- DeWitt, W.S., Emerson, R.O., Lindau, P., Vignali, M., Snyder, T.M., Desmarais, C., Sanders, C., Utsugi, H., Warren, E.H., McElrath, J., et al. (2015). Dynamics of the cytotoxic T cell response to a model of acute viral infection. *J. Virol.* **89**, 4517–4526.
- Engler, J.B., Kursawe, N., Solano, M.E., Patas, K., Wehrmann, S., Heckmann, N., Lühder, F., Reichardt, H.M., Arck, P.C., Gold, S.M., and Friese, M.A. (2017). Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy. *Proc. Natl. Acad. Sci. USA* **114**, E181–E190.
- Finkelsztejn, A., Brooks, J.B., Paschoal, F.M., Jr., and Fragoso, Y.D. (2011). What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. *BJOG* **118**, 790–797.
- Gold, S.M., and Voskuhl, R.R. (2016). Pregnancy and multiple sclerosis: from molecular mechanisms to clinical application. *Semin. Immunopathol.* **38**, 709–718.
- Han, A., Gianville, J., Hansmann, L., and Davis, M.M. (2014). Linking T-cell receptor sequence to functional phenotype at the single-cell level. *Nat. Biotechnol.* **32**, 684–692.
- Hohlfeld, R., Dornmair, K., Meinl, E., and Wekerle, H. (2016a). The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. *Lancet Neurol.* **15**, 198–209.
- Hohlfeld, R., Dornmair, K., Meinl, E., and Wekerle, H. (2016b). The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. *Lancet Neurol.* **15**, 317–331.
- Howie, B., Sherwood, A.M., Berkebile, A.D., Berka, J., Emerson, R.O., Williamson, D.W., Kirsch, I., Vignali, M., Rieder, M.J., Carlson, C.S., and Robins, H.S. (2015). High-throughput pairing of T cell receptor  $\alpha$  and  $\beta$  sequences. *Sci. Transl. Med.* **7**, 301ra131.
- Iannello, A., Rolla, S., Maglione, A., Ferrero, G., Bardina, V., Inaudi, I., De Mercanti, S., Novelli, F., D'Antuono, L., Cardaropoli, S., et al. (2019). Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis. *Front. Immunol.* **9**, 3075.
- Jelcic, I., Al Nimer, F., Wang, J., Lentsch, V., Planas, R., Jelcic, I., Madjovski, A., Ruhmann, S., Faigle, W., Frauenknecht, K., et al. (2018). Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. *Cell* **175**, 85–100.e23.
- Kahn, D.A., and Baltimore, D. (2010). Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance. *Proc. Natl. Acad. Sci. USA* **107**, 9299–9304.
- Kirsch, I., Vignali, M., and Robins, H. (2015). T-cell receptor profiling in cancer. *Mol. Oncol.* **9**, 2063–2070.
- Munoz-Suano, A., Kallikourdis, M., Sarris, M., and Betz, A.G. (2012). Regulatory T cells protect from autoimmune arthritis during pregnancy. *J. Autoimmun.* **38**, J103–J108.
- Planas, R., Metz, I., Martin, R., and Sospedra, M. (2018). Detailed characterization of T cell receptor repertoires in multiple sclerosis brain lesions. *Front. Immunol.* **9**, 509.
- Pozzilli, C., De Giglio, L., Barletta, V.T., Marinelli, F., Angelis, F.D., Gallo, V., Pagano, V.A., Marini, S., Piattella, M.C., Tomassini, V., et al. (2015). Oral contraceptives combined with interferon beta in multiple sclerosis. *Neurol. Neuroimmunol. Neuroinflamm.* **2**, e120.
- Robins, H.S., Campregher, P.V., Srivastava, S.K., Wacher, A., Turtle, C.J., Khsai, O., Riddell, S.R., Warren, E.H., and Carlson, C.S. (2009). Comprehensive assessment of T-cell receptor  $\beta$ -chain diversity in alpha-beta T cells. *Blood* **114**, 4099–4107.
- Robins, H., Desmarais, C., Matthis, J., Livingston, R., Andriesen, J., Reijnen, H., Carlson, C., Nepom, G., Yee, C., and Cersosetti, K. (2012). Ultra-sensitive detection of rare T cell clones. *J. Immunol. Methods* **375**, 14–19.

Rowe, J.H., Ertelt, J.M., Xin, L., and Way, S.S. (2012). Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. *Nature* 490, 102–106.

Samstein, R.M., Josefowicz, S.Z., Arvey, A., Treuting, P.M., and Rudensky, A.Y. (2012). Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. *Cell* 150, 29–38.

Sherwood, A., Desmarais, C., and Emerson, R.O. (2015). TCRB time course. <https://clients.adaptivebiotech.com/pub/healthy-adult-time-course-TCRB>. Voskuhl, R.R., Wang, H., Wu, T.C., Sicotte, N.L., Nakamura, K., Kurth, F., Itoh, N., Bardens, J., Bernard, J.T., Corboy, J.R., et al. (2016). Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. *Lancet Neurol.* 15, 35–46.



## STAR★METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE                                  | SOURCE   | IDENTIFIER                         |
|--|--|------------------------------------|
| <b>Antibodies</b>                                    |  |                                    |
| CD195 (CCR5) PE (HEK/1/85a)                          | Biolegend  | Cat# 313707; RRID:AB_345307        |
| CD45RO PerCP/Cy5.5 (UCHL1)                           | Biolegend  | Cat# 304221; RRID:AB_1575041       |
| CD28 PE/Cy7 (CD28.2)                                 | Biolegend  | Cat# 302926; RRID:AB_10644005      |
| CD197(CCR7) APC (TG8/CCR7)                           | Biolegend  | N/A                                |
| CD8 APC/Cy7 (RPA-T8)                                 | Biolegend  | Cat# 301016; RRID:AB_314134        |
| CD4 V500 (RPA-T4)                                    | BD   | Cat# 560768; RRID:AB_1937323       |
| CD62L Pacific Blue™ (DREG-56)                        | Biolegend  | Cat# 304826; RRID:AB_2186977       |
| CD195(CCR5) FITC (HEK/1/85a)                         | Biolegend  | Cat# 313705; RRID:AB_345305        |
| CD25 PE (BC96)                                       | Biolegend  | Cat# 302606; RRID:AB_314276        |
| CD127 PerCP/Cy5.5 (A019D5)                           | Biolegend  | Cat# 351322; RRID:AB_10897104      |
| CD39 PE/Cy7 (A1)                                     | Biolegend  | Cat# 328212; RRID:AB_2099950       |
| CCR2 APC (TG5/CCR2)                                  | Biolegend  | N/A                                |
| CD28 pure - functional grade (15E8)                  | Miltenyi Biotec  | Cat# 130-093-375; RRID:AB_1036134  |
| CD40 pure - functional grade (HB14)                  | Miltenyi Biotec  | Cat# 130-094-133; RRID:AB_10839704 |
| CD3 pure - functional grade (OKT3)                   | Miltenyi Biotec  | Cat# 130-093-387; RRID:AB_1036144  |
| CD4 APC (Vit4)                                       | Miltenyi Biotec  | Cat# 130-092-374; RRID:AB_871680   |
| Anti-Biotin FITC (Bio3-18E7)                         | Miltenyi Biotec  | Cat# 130-090-857; RRID:AB_244257   |
| CD69 APC-Vio770 (FN50)                               | Miltenyi Biotec  | Cat# 130-099-907; RRID:AB_2661137  |
| CD14 VioGreen (TÜK4)                                 | Miltenyi Biotec  | Cat# 130-096-875; RRID:AB_2660175  |
| CD8 VioGreen (BW135/80)                              | Miltenyi Biotec  | Cat# 130-096-902; RRID:AB_2660905  |
| CD20 VioGreen (LT20)                                 | Miltenyi Biotec  | Cat# 130-096-904; RRID:AB_2660933  |
| CD154 VioBlue (5C8)                                  | Miltenyi Biotec  | Cat# 130-096-217; RRID:AB_10829767 |
| TNF- $\alpha$ PE (cA2)                               | Miltenyi Biotec  | Cat# 130-091-651; RRID:AB_244203   |
| CD45RA Pacific Blue™ (HI 100)                        | Biolegend  | Cat# 304123; RRID:AB_2174122       |
| CD27 FITC (O323)                                     | Biolegend  | Cat# 302806; RRID:AB_31429         |
| <b>Chemicals, Peptides, and Recombinant Proteins</b> |  |                                    |
| PepTivator MOG                                       | Miltenyi Biotec  | Cat# 130-096-770                   |
| PepTivator MBP Isoform 1                             | Miltenyi Biotec  | Cat# 130-096-763                   |
| PepTivator PLP                                       | Miltenyi Biotec  | Cat# 130-097-274                   |
| PepTivator EBV EBNA-1                                | Miltenyi Biotec  | Cat# 130-093-613                   |
| RPMI-1640 medium + GlutaMAX                          | GIBCO, Thermo Fisher Scientific  | Cat# 11554516                      |
| human AB serum                                       | Sigma Aldrich  | Cat# H4522-100ML                   |
| TexMACS medium                                       | Miltenyi Biotec  | Cat# 130-097-196                   |
| IL-2 (Proleukin)                                     | Novartis   | N/A                                |
| Inside Stain Kit                                     | Miltenyi Biotec  | Cat# 130-090-477                   |
| <b>Critical Commercial Assays</b>                    |  |                                    |
| Anti-human CD4 particles                             | BD Imag, BD Bioscience   | Cat# 557767; RRID:AB_398629        |
| Anti-human CD8 particles                             | BD imag, BD Bioscience   | Cat# 557766; RRID:AB_398628        |
| DNeasy Blood and Tissue Kit                          | QIAGEN   | Cat# 69506                         |
| ImmunoSEQ™ Assay                                     | Adaptive Biotechnologies; <a href="#">Carlson et al., 2013</a> ; <a href="#">Robins et al., 2012</a> ; <a href="#">Robins et al., 2009</a> | N/A                                |
| PairSEQ™ Assay                                       | Adaptive Biotechnologies; <a href="#">Howie et al., 2015</a>   | N/A                                |

(Continued on next page)

| <b>Continued</b>   |                                       |  |
|--|---------------------------------------|--|
| REAGENT or RESOURCE  | SOURCE                                | IDENTIFIER   |
| CD154 MicroBead Kit, human   | Miltenyi Biotec                       | Cat# 130-092-658   |
| CD3 MicroBeads, human  | Miltenyi Biotec                       | Cat# 130-050-101   |
| MS columns   | Miltenyi Biotec                       | Cat# 130-042-201   |
| Deposited Data   |                                       |  |
| Longitudinal MS and HC pregnancy TCR seq data                          | This paper                            | <a href="https://doi.org/10.21417/B7B012">https://doi.org/10.21417/B7B012</a>  |
| Time course healthy female TCR seq data                                | <a href="#">Sherwood et al., 2015</a> | <a href="https://doi.org/10.21417/B7J01X">https://doi.org/10.21417/B7J01X</a>  |
| Software and Algorithms  |                                       |  |
| R version 3.2  | R Project for Statistical Computing   | RRID:SCR_001905; <a href="http://www.r-project.org/">http://www.r-project.org/</a>   |
| FlowJo   | FlowJo                                | RRID:SCR_008520; <a href="https://www.flowjo.com">https://www.flowjo.com</a>   |
| GraphPad Prism 5   | GraphPad Software                     | RRID:SCR_002798; <a href="https://www.graphpad.com/">https://www.graphpad.com/</a>   |
| Uniform Manifold Approximation and Projection (UMAP) Plug-in to FlowJo | FlowJo                                | <a href="https://arxiv.org/abs/1802.03426">arXiv:1802.03426</a> ; <a href="https://www.flowjo.com/exchange/">https://www.flowjo.com/exchange/</a>                                  |
| ImmunoSEQ™ Analyzer 2.0  | Adaptive Biotechnologies              | N/A; <a href="https://www.adaptivebiotech.com/products-services/immunoseq/immunoseq-analyzer/">https://www.adaptivebiotech.com/products-services/immunoseq/immunoseq-analyzer/</a> |
| ImmunoSEQ™ Analyzer 3.0  | Adaptive Biotechnologies              | N/A; <a href="https://www.adaptivebiotech.com/products-services/immunoseq/immunoseq-analyzer/">https://www.adaptivebiotech.com/products-services/immunoseq/immunoseq-analyzer/</a> |

## LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stefan M. Gold ([stefan.gold@zmnh.uni-hamburg.de](mailto:stefan.gold@zmnh.uni-hamburg.de)). This study did not generate new unique reagents or materials.

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Subjects and recruitment

MS Patients were recruited through the Multiple Sklerose Tagesklinik of the Universitätsklinikum Hamburg-Eppendorf. Healthy controls were recruited through the Klinik für Geburtshilfe und Pränatalmedizin, Universitätsklinik Hamburg-Eppendorf. The study was approved by the local ethics commission (Ethik-Kommission der Hamburger Ärztekammer; Approval No: PV3558, No: PV3694). All participants gave informed consent and were remunerated for time and effort. Female MS patients were selected from our study cohort based on sample availability and confirmed MS diagnosis. Healthy women were selected to match age, sex of the child, and parity (see [Table S1](#)). All mothers had single pregnancies. All MS patients were free of disease-modifying therapies (DMTs) during pregnancy. At the pre-pregnancy time point, one patient received DMT (interferon  $\beta$ -1a; MS42) and one patient was in relapse management and received steroid treatment (1mg for 3 days; blood sampled before second infusion; MS23). All but two patients (MS 41 DMT (interferon  $\beta$ -1a), MS23 DMT (dimethyl fumarate)) remained free of DMTs until after the last blood sample (three months post partum). Details on DMTs are provided in [Table S1](#).

## METHOD DETAILS

### Blood sampling and processing

Blood samples of MS patients were collected before, during and after pregnancy: before conception (Pre), in trimester 1 between week 10 and 14 of gestation (Tri1), in trimester 2 between week 22 and 24 (Tri2), in trimester 3 between week 30 and 36 (Tri3) and three months post partum (Post). Healthy controls gave blood samples at the same time points during pregnancy and post partum (but pre-pregnancy samples were not available for controls). Blood was collected in EDTA coated tubes (Sarstedt, Nümbrecht, Germany) and peripheral blood mononuclear cells (PBMCs) were isolated by a 30min gradient centrifugation at 863xg using Biocoll Separating Solution (Biochrom, Berlin, Germany), followed by two washing steps. Cells were then cryopreserved in RPMI medium (PAN-Biotech, Aidenbach, Germany) with 25% fetal calf serum (Biochrom) and 10% DMSO (AppliChem, Darmstadt, Germany)

and stored in liquid nitrogen until further analysis. During experimental procedures, the experimenters were not blinded. A differential blood count was performed on full blood using a Coulter AC\*T Diff (Beckmann Coulter, Brea, CA, USA).

### Flow cytometry

After a short resting period, fresh blood samples were incubated with antibody cocktail (CD45RA PB (HI 100), CD27 FITC (O323), CCR5 PE (HEK/1/85a), CD45RO PerCP/Cy5.5 (UCHL1), CD28 PE/Cy7 (CD28.2), CCR7 APC (TG8/CCR7), CD8 APC/Cy7 (RPA-T8), (all Biolegend, San Diego, CA, USA); CD4 V500 (RPA-T4; BD Bioscience, San José, CA, USA) or (CD62L PB (DREG-56), CCR5 FITC (HEK/1/85a), CD25 PE (BC96), CD127 PerCP/Cy5.5 (A019D5), CD39 PE/Cy7 (A1), CCR2 APC (TG5/CCR2), (all Biolegend); CD4 V500 (RPA-T4; BD Bioscience)) in the dark at room temperature, then erythrocytes were lysed with BD FACS Lysing Solution (BD Bioscience) and washed twice in PBS (520xg, 5min, 4°C). Samples were measured on a FACS Canto II (BD Bioscience). Data were analyzed using FloJo software (FlowJo, LLC., Ashland, OR, USA). Dimensionality reduction was performed on a concatenated dataset after downsampling lymphocytes positive for either CD8, CD4, or both to 10000 events (approx. 750000 events). Uniform Manifold Approximation and Projection (UMAP) plugin from FlowJo was used (Euclidian distance, nearest neighbor: 15 and minimum distance: 0.5, channels: CD4, CD8, CCR5, CD45RO, CD45RA and CCR7). To visually display change over time, another downsampling to 20000 events of the concatenated dataset was performed. Classical manual gating was performed for depicted T cell subsets.

### Identification of antigen-specific CD4<sup>+</sup> T cells

Fresh PBMCs from patient MS15 were isolated by density gradient centrifugation (Biocoll, Biochrom) and resuspended at a concentration of  $2 \times 10^7$ /ml in RPMI 1640 medium supplemented with GlutaMAX (GIBCO, Thermo Fischer Scientific Darmstadt, Germany) and 5% (v/v) human AB serum (Sigma Aldrich, Schnellendorf, Germany). Myelin and EBNA-1-specific CD4<sup>+</sup> T cells were enriched according to the Antigen-Reactive T Cell Enrichment (ARTE) protocol (Bacher et al., 2013) with modifications as described.  $9 \times 10^7$  cells were stimulated for 6 h with MOG, MBP1 and PLP peptide pools and  $3.8 \times 10^7$  cells were stimulated with EBNA-1 peptide pool (each 0.6 nmol/peptide/ml) in the presence of 1  $\mu$ g/ml CD40 (clone HB14) functional grade pure antibody (all Miltenyi Biotec, Bergisch Gladbach, Germany). Activated CD154<sup>+</sup> T cells were magnetically enriched (CD154 MicroBead Kit and MS columns, Miltenyi Biotec) and stained with CD4 APC (Vit4), CD154 (via anti-Biotin-FITC, Bio3-18E7), CD69 APC-Vio770 (FN50), CD14 VioGreen (TÜK4), CD8 VioGreen (BW135/80) and CD20 VioGreen (LT20) antibodies (all Miltenyi Biotec). To further increase purity, antigen-reactive CD4<sup>+</sup>/CD154<sup>+</sup>/CD69<sup>+</sup> T cells were FACS-sorted (Influx cell sorter; BD Biosciences). About 2500 (myelin) or 1000 (EBNA-1) isolated cells were expanded for 8 days with  $2.5 \times 10^6$  irradiated allogenic feeder cells in a 48-well plate in TexMACS medium (Miltenyi Biotec) supplemented with 30 ng/ml anti-CD3 (OKT-3; Miltenyi Biotec), 200 IU/ml IL-2 (Proleukin; Novartis, Nürnberg, Germany), 100 IU/ml Penicillin, 100  $\mu$ g/ml Streptomycin (both Sigma Aldrich), 20  $\mu$ M  $\beta$ -Mercaptoethanol (GIBCO, Thermo Fischer Scientific) and 5% human AB serum. The cells were split and medium was replenished as needed. After resting in RPMI 1640 medium + 5% human AB serum for 2 days, expanded cells were restimulated for 7 hours with the initial myelin antigens or EBNA-1 in the presence of 1  $\mu$ g/ml CD28 functional grade pure antibody (15E8; Miltenyi Biotec) and autologous CD3-depleted PBMCs in a 1:1 ratio (CD3 MicroBeads, Miltenyi Biotec). After 3 hours, 1  $\mu$ g/ml Brefeldin A (Sigma Aldrich) was added. The cells were stained with CD4 APC and CD14 VioGreen, fixed and permeabilized (Inside Stain Kit, Miltenyi Biotec) and stained intracellularly with CD154 VioBlue (5C8) and TNF- $\alpha$  PE (cA2, both Miltenyi Biotec). Activated CD154<sup>+</sup>/TNF- $\alpha$ <sup>+</sup> T cells and non-activated CD154<sup>-</sup>/TNF- $\alpha$ <sup>-</sup> T cells were FACS-sorted. Cells at several steps throughout the expansion procedure were shock-frozen in liquid nitrogen ( $1.5 \times 10^5$  cells at time points 5/6 and  $5 \times 10^5$  cells at time points 1-4, see Figure S3) for later DNA isolation and TCR sequencing as described below.

### Cell purification and DNA extraction

PBMCs were thawed, counted and separated into 3 parts: at least  $10^6$  PBMCs were directly pelleted and shock frozen, the other 2 parts were used for magnetic cell sorting of CD4<sup>+</sup> and CD8<sup>+</sup> cells. CD4<sup>+</sup> and CD8<sup>+</sup> cells were isolated separately in parallel procedures using positive selection kits (BD Imag; BD Bioscience) according to the manufacturer's instructions (using 30  $\mu$ L of magnetic particles for up to  $10^7$  cells). After isolation, CD4<sup>+</sup> and CD8<sup>+</sup> cells were pelleted and shock-frozen. To extract DNA, cell pellets were thawed and processed with the DNeasy Blood and Tissue Kit (QIAGEN, Hilden, Germany), following the manufacturer's protocol for tissue, then stored at  $-20^\circ\text{C}$  until shipment.

### Immunosequencing

Immunosequencing of the CDR3 regions of human TCR $\beta$  chains was performed using the ImmunoSEQ™ Assay (Adaptive Biotechnologies, Seattle, WA, USA). Extracted genomic DNA was amplified in a bias-controlled multiplex PCR, followed by high-throughput sequencing. Sequences were collapsed and filtered in order to identify and quantitate the absolute abundance of each unique TCR $\beta$  CDR3 region for further analysis as previously described (Carlson et al., 2013; Robins et al., 2009, 2012).

TCR $\alpha$   $\times$  TCR $\beta$  pairs were identified using the PairSEQ™ Assay. Here, the TCR $\alpha$  and TCR $\beta$  loci are immunosequenced on a single 96 well plate, using the ImmunoSEQ™ Assay as described above. This yields an occupancy vector with 96 components for each TCR $\alpha$  and TCR $\beta$  rearrangement. Comparison with the null probabilities given by random subset sampling allow statistically confident pairing of TCR $\alpha$  and TCR $\beta$  with sufficiently similar occupancy vectors, and a multiple testing correction procedure involving a simulated null distribution enforces a false discovery rate of 1% (Howie et al., 2015).

## QUANTIFICATION AND STATISTICAL ANALYSIS

Clonality was defined as 1- Pielou's evenness (Kirsch et al., 2015) and was calculated on productive rearrangements by:  $1 + \frac{N}{\sum_i p_i \log_2(p_i) / \log_2(N)}$  where  $p_i$  is the proportional abundance of rearrangement  $i$  and  $N$  is the total number of rearrangements.

Clonality values range from 0 to 1 and describe the shape of the frequency distribution: clonality values approaching 0 indicate a very even distribution of frequencies, whereas values approaching 1 indicate an increasingly asymmetric distribution in which a few clones are present at high frequencies. Changes in TCR clonality, clonotype frequencies, lymphocyte frequencies and phenotype during pregnancy were tested using Wilcoxon matched-pairs signed rank test (trimester 1 versus trimester 3). Group differences of absolute and relative change of clonality and the cumulative frequency of top clonotypes was performed using Mann-Whitney-U test. In the afore mentioned tests,  $P$ -values  $< 0.05$  were considered statistically significant. Statistical details of each experiment are reported in the respective figure legends. Statistical analysis was performed in R version 3.2. and GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). So called "candidate clones" were defined as clones that had significantly lower frequency in trimester 3 compared to trimester 1 and significantly higher frequency post partum compared to trimester 3, i.e. these clones contracted from trimester 1 to trimester 3 and expanded from trimester 3 to post partum. These clones were identified based on a statistical method performed as described (DeWitt et al., 2015), with minor variations to statistical parameters involving implantation of a minimum total template count filter of 5 templates, and incorporation of multiple testing correction with the Benjamini-Hochberg (BH) method. After multiple-testing correction, the threshold of significance was  $\alpha < 0.01$  on the BH adjusted  $P$ -values.

Clonotype frequency data was exported with ImmunoSEQ Analyzer 3.0 (Adaptive Biotechnologies) as frequency of all unique productive TCR $\beta$  CDR3 amino acid sequences. Candidate clonotypes frequencies (see Data S1 and S2) were extracted with ImmunoSEQ Analyzer 2.0 (Adaptive Biotechnologies), displaying frequency of clones as percentage of all rearrangements.

## DATA AND CODE AVAILABILITY


The complete data from this study are available for download and analysis at an open-access, shareable repository (ImmuneACCESS). Data may be accessed using the following link after creating a free account: <https://doi.org/10.21417/B7B012>.

Data on time course of healthy females is accessible at: <https://doi.org/10.21417/B7J01X> (Sherwood et al., 2015). No new code was generated in this study.

**Supplemental Information**

**T Cell Repertoire Dynamics  
during Pregnancy in Multiple Sclerosis**


**Caren Ramien, Erik C. Yusko, Jan Broder Engler, Stefanie Gamradt, Kostas Patas, Nils Schweingruber, Anne Willing, Sina Cathérine Rosenkranz, Anke Diemert, Anja Harrison, Marissa Vignali, Catherine Sanders, Harlan S. Robins, Eva Tolosa, Christoph Heesen, Petra C. Arck, Alexander Scheffold, Kenneth Chan, Ryan O. Emerson, Manuel A. Friese, and Stefan M. Gold**



**Figure S1: T-cell repertoire fluctuations in three young healthy non-pregnant females over the course of 13 months.**


**(A)** Time course of T-cell repertoire clonality in PBMCs of healthy non-pregnant women.

Heatmap **(B)** and cumulative frequencies **(C)** shown for the 100 most abundant clonotypes in each woman over time. Refers to **Figure 1** and **Figure 2**.



**Figure S2: Pregnancy changes in lymphocyte numbers, frequencies and phenotype.**


Overall count of T-cells within the PBMC pool shown for MS patients (A) and healthy controls (B) throughout pregnancy. Overview of multi-parametric phenotypic T-cell analysis (C) visualized by dimensionality reduction (UMAP) throughout pregnancy for MS patients (top) and healthy controls (bottom). Darker coloring indicates higher abundance of cells falling into this cluster. Staining intensity of the clusters for each marker within the UMAP is displayed in (D), orange representing highly positive populations, blue the negative populations. Frequencies of major T-cell subsets in MS patients (E) and healthy controls (F) throughout pregnancy. In all panels, individual values for each subject (A:  $n = 11$ , B:  $n = 12$ , C-F:  $n = 11$ ) and the median are shown;  $P$  values are derived from Wilcoxon matched-pairs signed rank test comparing trimester 1 to trimester 3. Refers to **Figure 1**.



**Figure S3: Experimental setup for expansion and characterization of EBV and myelin-specific CD4<sup>+</sup> T-cells in patient MS15.**

(A) Workflow of T-cell stimulation with EBNA-1 or myelin peptide pool and subsequent expansion of the antigen specific cells before re-stimulation. Circled numbers indicate the time points at which samples were taken for sequencing and the corresponding sample IDs in the immuneACCESS public database (<https://doi.org/10.21417/B7J01X>). Checks for feeder cell contamination in EBNA-1 and myelin pool restimulated samples are shown in (B) and (C), respectively. Minimal clonotype overlap (green dots) indicates negligible feeder contamination. Refers to **Figure 3** and **Figure S4**.





**Figure S4: EBNA-1 and myelin-specific clonotypes tracked over time in patient MS15.**

Frequencies of all clonotypes reactivated by EBNA-1 (A) or the myelin pool (B) and found in at least one time point throughout pregnancy in the CD4<sup>+</sup> compartment are displayed (see sequenced samples 6, **Figure S3A**). Three EBNA-1 specific clonotypes were found among the top 100 most frequent CD4<sup>+</sup> clonotypes during relapse in MS15 (see **Figure 3**). Data are represented as individual clonotypes of patient MS15 and median. *P* values are derived from Wilcoxon matched-pairs signed rank test comparing trimester 1 to trimester 3. Refers to **Figure 3** and **Figure S3**.

**Table S1:** Demographic and clinical characteristics of mothers with MS and healthy control mothers matched for age, parity, and sex of child. For MS patients, history of disease modifying therapy (DMT) is displayed, for healthy controls this is not applicable (-). Related to STAR\*Methods.

| ID    | age | parity* | sex of child | DMT naive | DMT prior to Pre time point | Treatment-free time prior to Pre time point (months) | DMT between Pre and Tri1 | Time between Pre and Tri1 (months) |
|-------|-----|---------|--------------|-----------|-----------------------------|--|--------------------------|------------------------------------|
| MS.1  | 28  | 1       | f            | Yes       | -                           | -  | No                       | 16                                 |
| HC.21 | 29  | 1       | f            | -         | -                           | -  | -                        | -                                  |
| MS.13 | 34  | 1       | m            | Yes       | -                           | -  | No                       | 3                                  |
| HC.3  | 31  | 1       | m            | -         | -                           | -  | -                        | -                                  |
| MS.15 | 25  | 1       | f            | Yes       | -                           | -  | No                       | 3,5                                |
| HC.17 | 21  | 1       | f            | -         | -                           | -  | -                        | -                                  |
| MS.23 | 28  | 1       | m            | No        | IFN/glatiramer acetate      | 2  | No                       | 15                                 |
| HC.10 | 31  | 1       | m            | -         | -                           | -  | -                        | -                                  |
| MS.25 | 29  | 1       | m            | Yes       | -                           | -  | No                       | 6                                  |
| HC.5  | 24  | 1       | m            | -         | -                           | -  | -                        | -                                  |
| MS.31 | 33  | 1       | f            | No        | IFN                         | 4  | No                       | 16                                 |
| HC.16 | 33  | 1       | f            | -         | -                           | -  | -                        | -                                  |
| MS.33 | 32  | 1       | f            | No        | IFN                         | 1  | No                       | 12                                 |
| HC.13 | 29  | 1       | f            | -         | -                           | -  | -                        | -                                  |
| MS.40 | 40  | 1       | f            | Yes       | -                           | -  | No                       | 2                                  |
| HC.12 | 36  | 1       | f            | -         | -                           | -  | -                        | -                                  |
| MS.41 | 32  | 1       | f            | No        | IFN, azathioprine           | 6  | No                       | 8                                  |
| HC.18 | 33  | 1       | f            | -         | -                           | -  | -                        | -                                  |
| MS.42 | 34  | 1       | f            | No        | IFN                         | 5,5  | Yes (IFN)                | 13                                 |
| HC.6  | 31  | 1       | f            | -         | -                           | -  | -                        | -                                  |
| MS.52 | 35  | 2       | m            | Yes       | -                           | -  | No                       | 5                                  |
| HC.2  | 36  | 2       | m            | -         | -                           | -  | -                        | -                                  |
| HC.7  | 30  | 1       | m            | -         | -                           | -  | -                        | -                                  |

\* 1 = pregnant with first child during the study, 2 = pregnant with second child during the study